Author: John Pinching

Company aims to expand treatment options for relapsed or refractory multiple myeloma

Combination therapy moves into late‑stage testing after encouraging earlier results

Company prepares regulatory filings after treatment shows significant reduction in disease flare risk

New consultancy aims to deliver personalised senior expertise in healthcare communications

Results show disease control and tumour shrinkage with GNS561 and MEK inhibitor combination